Markus

[Markus @MarkusMeyerMD]

EarlBakken Medtronicfounder on #whywepace60bpm

[Markus @MarkusMeyerMD]

Can faster heart rates ELEVATE lives?
In 30 years from bench to patient.

https://t.co/5KpNzViYSu

[Markus @MarkusMeyerMD]

The president does not have chronic venous insufficiency - he has elevated cardiac filling pressures from bradycardia-mediated HFpEF that put him at risk for AF.

[Markus @MarkusMeyerMD]

Atria have a functional conduction system that is accessible for CSP

https://t.co/9dQgyJ9usv

[Markus @MarkusMeyerMD]

Another way to give HFpEF patients more room to breathe

https://t.co/T5ggfTQGSQ

[Markus @MarkusMeyerMD]

Not just HFpEF

https://t.co/ugmX3Zq6yC

[Markus @MarkusMeyerMD]

2024 HCM Guidelines are failing HCM patients with preserved EF again!

BETABLOCKERS do NOT improve diastolic function. They are HFpEF in a pill.

Not indicated in nHCN

https://t.co/DEiVHyeRaG.…

[Markus @MarkusMeyerMD]

@CircAHA Betablockers do not improve diastolic function = collective incompetence of the experts.

Not indicated in nHCN

https://t.co/HSVUoXxoES

[Markus @MarkusMeyerMD]

@drjohnm Obesity-related rise in HTN/filling pressures.
Lines up with BMI trends and seems to have reached a tipping point. AF would look similarly.

[Markus @MarkusMeyerMD]

@NicoleHabelMD @UVMLarnerMed @UVMMedCenter @lusty63 @MaggieInfeld Important first in HFpEF patients without standard PPM indication - EP Center of Excellence

[Markus @MarkusMeyerMD]

@JuliaSellerm @PatriciaPalau1 shouldn't we all have a bigger heart ?
Congrats team Patricia and Julio!

https://t.co/XV19NkqI5c

[Julia Seller @JuliaSellerm]

📁 https://t.co/qOI4kbXsEP

[Markus @MarkusMeyerMD]

@KramerWahlberg @UVMDeptMed @HRSonline @uvmcvri @nih_nhlbi @umichmedicine @MaggieInfeld Great new insights, Kramer !

Early signals that "rate shaping" of the LV may actually be feasible. More to come.

[Markus @MarkusMeyerMD]

myPACE forever ??

3-year exposure to personalized accelerated physiological pacing.

AHA Poster (#2240 and 2260) Monday 1:30-2:45p.

[Markus @MarkusMeyerMD]

More background on personalized accelerated physiological pacing as a treatment approach for diastolic dysfunction.

https://t.co/WzpAfUIPmg

[Markus @MarkusMeyerMD]

Are higher heart rates better in HFpEF ?https://t.co/FLezx12B9N

[Markus @MarkusMeyerMD]

@FudimMarat @lamcardio @AdriaanVoors @Jcontreras75 @novonordisk @HFpEF @KSharmaMD @udi_fainberg @CecilieHolse @markcpetrie20 @texhern Maybe not much inflammation in advanced HFpEF

https://t.co/qiIrEGa5CI

[Markus @MarkusMeyerMD]

No evidence for inflammation in human myocardial LV transcriptome in advanced HFpEF

https://t.co/odlbbADGTv

[Markus @MarkusMeyerMD]

Without an evidence basis beta-blockers, remain the #1 drug prescribed in HFpEF (flawed rationale and outdated treatment recommendations)

https://t.co/eQmP97bpu0

[Markus @MarkusMeyerMD]

@arnoldgehrke Without an evidence base beta-blockers remain the #1 medication class in HFpEF (due to a flawed rationale).

[Suzanne Arnold @suzannevarnold]

Not all patients with “heart failure” need or benefit from beta blockers. Our analysis showing the potential for an increased risk for HF hospitalization with BB in patients with higher EFs (particularly over 60%). https://t.co/MSD9JN5pvS